Intradermal powder immunization with protein-containing vaccines

References

• Varmus H, Klausner R, Zerhouni E, Acharya T, Daar AS, Singer PA. Public health. Grand challenges in global health. Science 302(5644), 398–399 (2003).
   PubMed Web of Science ®Google Scholar
• Senior K. New vaccination technologies that make needles redundant. Lancet Infect. Dis. 11(1), 16–17 (2011).
   Google Scholar
• Amorij JP, Hinrichs WLj, Frijlink HW, Wilschut JC, Huckriede A. Needle-free influenza vaccination. Lancet Infect. Dis. 10(10), 699–711 (2010).
   PubMed Web of Science ®Google Scholar
• Mitragotri S. Immunization without needles. Nat. Rev. Immunol. 5(12), 905–916 (2005).
   PubMed Web of Science ®Google Scholar
• Prausnitz MR, Langer R. Transdermal drug delivery. Nat. Biotechnol. 26(11), 1261–1268 (2008).
   PubMed Web of Science ®Google Scholar
• WHO. Safety of Injections: Global Facts and Figures. WHO, Geneva, Switzerland (2004).
   Google Scholar
• Kermode M. Unsafe injections in low-income country health settings: need for injection safety promotion to prevent the spread of blood-borne viruses. Health Promot. Int. 19(1), 95–103 (2004).
   PubMed Web of Science ®Google Scholar
• WHO. State of the world’s vaccines and immunizations. JAMA 288(20), 2532 (2002).
   Google Scholar
• Wilburn SQ, Eijkemans G. Preventing needle stick injuries among healthcare workers. J. Adv. Nurs. 50(4), 450–450 (2005).
   Google Scholar
• CDC. Impact of vaccines universally recommended for children – United States, 1990–1998. MMWR 48, 243–248 (1999).
   PubMedGoogle Scholar
• Das P. Revolutionary vaccine technology breaks the cold chain. Lancet Infect. Dis. 4(12), 719 (2004).
   PubMedGoogle Scholar
• Jódar L, LaForce FM, Ceccarini C, Aguado T, Granoff DM. Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet 361(9372), 1902–1904 (2003).
   PubMed Web of Science ®Google Scholar
• Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6(2), 148–158 (2006).
   PubMed Web of Science ®Google Scholar
• Girardi M. Cutaneous perspectives on adaptive immunity. Clin. Rev. Allergy Immunol. 33(1–2), 4–14 (2007).
   Google Scholar
• Zhaori G, Sun M, Ogra PL. Characteristics of the immune response to poliovirus virion polypeptides after immunization with live or inactivated polio vaccines. J. Infect. Dis. 158(1), 160–165 (1988).
   Google Scholar
• Fernandez-De Castro J, Kumate-Rodriguez J, Sepulveda J, Ramirez-Isunza JM, Valdespino-Gomez JL. [Measles vaccination by the aerosol method in Mexico]. Salud Publica Mex. 39(1), 53–60 (1997).
   PubMed Web of Science ®Google Scholar
• Lin WH, Griffin DE, Rota PA et al. Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques. Proc. Natl Acad. Sci. USA 108(7), 2987–2992 (2011).
   PubMed Web of Science ®Google Scholar
• Woodrow KA, Bennett KM, Lo DD. Mucosal vaccine design and delivery. Annu. Rev. Biomed. Eng. 14, 17–46 (2012).
   PubMed Web of Science ®Google Scholar
• Chase MW. Inhibition of experimental drug allergy by prior feeding of the sensitizing agent. Proc. Soc. Exp. Biol. Med. 61, 257–259 (1946).
   PubMed Web of Science ®Google Scholar
• Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat. Med. 11(4 Suppl.), S45–S53 (2005).
   PubMed Web of Science ®Google Scholar
• Canter J, Mackey K, Good LS et al. An outbreak of hepatitis B associated with jet injections in a weight reduction clinic. Arch. Intern. Med. 150(9), 1923–1927 (1990).
   PubMed Web of Science ®Google Scholar
• Jackson LA, Austin G, Chen RT et al.; Vaccine Safety Datalink Study Group. Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. Vaccine 19(32), 4703–4709 (2001).
   PubMed Web of Science ®Google Scholar
• Sullivan SP, Koutsonanos DG, Del Pilar Martin M et al. Dissolving polymer microneedle patches for influenza vaccination. Nat. Med. 16(8), 915–920 (2010).
   PubMed Web of Science ®Google Scholar
• Dean HJ, Chen D. Epidermal powder immunization against influenza. Vaccine 23(5), 681–686 (2004).
   PubMed Web of Science ®Google Scholar
• Ekwueme DU, Weniger BG, Chen RT. Model-based estimates of risks of disease transmission and economic costs of seven injection devices in sub-Saharan Africa. Bull. World Health Organ. 80(11), 859–870 (2002).
   PubMedGoogle Scholar
• Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. Microneedle-based vaccines. Curr. Top. Microbiol. Immunol. 333, 369–393 (2009).
   PubMedGoogle Scholar
• Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm. 289(1–2), 1–30 (2005).
   PubMed Web of Science ®Google Scholar
• Chen D, Endres RL, Erickson CA et al. Epidermal immunization by a needle-free powder delivery technology: immunogenicity of influenza vaccine and protection in mice. Nat. Med. 6(10), 1187–1190 (2000).
   PubMed Web of Science ®Google Scholar
• Maa YF, Ameri M, Shu C, Payne LG, Chen D. Influenza vaccine powder formulation development: spray-freeze-drying and stability evaluation. J. Pharm. Sci. 93(7), 1912–1923 (2004).
   PubMed Web of Science ®Google Scholar
• Glenn GM, Kenney RT. Mass vaccination: solutions in the skin. Curr. Top. Microbiol. Immunol. 304, 247–268 (2006).
   PubMed Web of Science ®Google Scholar
• Sandby-Møller J, Poulsen T, Wulf HC. Epidermal thickness at different body sites: relationship to age, gender, pigmentation, blood content, skin type and smoking habits. Acta Derm. Venereol. 83(6), 410–413 (2003).
   PubMed Web of Science ®Google Scholar
• Madison KC. Barrier function of the skin: ‘la raison d’être’ of the epidermis. J. Invest. Dermatol. 121(2), 231–241 (2003).
   PubMed Web of Science ®Google Scholar
• Torin Huzil J, Sivaloganathan S, Kohandel M, Foldvari M. Drug delivery through the skin: molecular simulations of barrier lipids to design more effective noninvasive dermal and transdermal delivery systems for small molecules, biologics, and cosmetics. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. doi:10.1002/wnan.147 (2011) (Epub ahead of print).
   Google Scholar
• Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp. Dermatol. 9(3), 165–169 (2000).
   PubMed Web of Science ®Google Scholar
• Kendall M, Rishworth S, Carter F, Mitchell T. Effects of relative humidity and ambient temperature on the ballistic delivery of micro-particles to excised porcine skin. J. Invest. Dermatol. 122(3), 739–746 (2004).
   PubMed Web of Science ®Google Scholar
• Holbrook KA, Odland GF. Regional differences in the thickness (cell layers) of the human stratum corneum: an ultrastructural analysis. J. Invest. Dermatol. 62(4), 415–422 (1974).
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Xiong GL, Haus E, Sackett-Lundeen L, Ashkenazi I, Maibach HI. Time-dependent variations of the skin barrier function in humans: transepidermal water loss, stratum corneum hydration, skin surface pH, and skin temperature. J. Invest. Dermatol. 110(1), 20–23 (1998).
   PubMed Web of Science ®Google Scholar
• Darlenski R, Fluhr JW. Influence of skin type, race, sex, and anatomic location on epidermal barrier function. Clin. Dermatol. 30(3), 269–273 (2012).
   Google Scholar
• Dean HJ, Fuller D, Osorio JE. Powder and particle-mediated approaches for delivery of DNA and protein vaccines into the epidermis. Comp. Immunol. Microbiol. Infect. Dis. 26(5-6), 373–388 (2003).
   PubMed Web of Science ®Google Scholar
• Hamilton JG. Needle phobia: a neglected diagnosis. J. Fam. Pract. 41(2), 169–175 (1995).
   PubMed Web of Science ®Google Scholar
• Liu Y. Utilization of the venturi effect to introduce micro-particles for epidermal vaccination. Med. Eng. Phys. 29(3), 390–397 (2007).
   PubMed Web of Science ®Google Scholar
• Kendall MAF, Quinlan NJ, Thorpe SJ, Ainsworth RW, Bellhouse BJ. Measurements of the gas and particle flow within a converging–diverging nozzle for high speed powdered vaccine and drug delivery. Exp. Fluids 37(1), 128–136 (2004).
   Web of Science ®Google Scholar
• Quinlan NJ, Kendall MAF, Bellhouse BJ, Ainsworth RW. Investigations of gas and particle dynamics in first generation needle-free drug delivery devices. Shock Waves 10(6), 395–404 (2001).
   Web of Science ®Google Scholar
• Kendall M, Mitchell T, Wrighton-Smith P. Intradermal ballistic delivery of micro-particles into excised human skin for pharmaceutical applications. J. Biomech. 37(11), 1733–1741 (2004).
   PubMed Web of Science ®Google Scholar
• Burkoth TL, Bellhouse BJ, Hewson G, Longridge DJ, Muddle AG, Sarphie DF. Transdermal and transmucosal powdered drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 16(4), 331–384 (1999).
   PubMed Web of Science ®Google Scholar
• Koutsonanos DG, Vassilieva EV, Stavropoulou A et al. Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci. Rep. 2, 357 (2012).
   PubMed Web of Science ®Google Scholar
• Abbas A, Lichtman A, Pober J. Cellular and Molecular Immunology. WB Saunders, PA, USA (2000).
   Google Scholar
• Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat. Rev. Immunol. 4(3), 211–222 (2004).
   PubMed Web of Science ®Google Scholar
• Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N. Engl. J. Med. 341(24), 1817–1828 (1999).
   PubMed Web of Science ®Google Scholar
• Alcock R, Cottingham MG, Rollier CS et al. Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Sci. Transl. Med. 2(19), 19ra12 (2010).
   PubMed Web of Science ®Google Scholar
• Pipkin PA, Minor PD. Studies on the loss of infectivity of live type 3 poliovaccine on storage. Biologicals 26(1), 17–23 (1998).
   Google Scholar
• Milstien JB, Galazka AM, Kartoglu Ü, Zaffran M. Temperature Sensitivity of Vaccines. WHO, Geneva, Switzerland (2006).
   Google Scholar
• Weir E, Hatch K. Preventing cold chain failure: vaccine storage and handling. CMAJ 171(9), 1050 (2004).
   Google Scholar
• Rogers B, Dennison K, Adepoju N, Dowd S, Uedoi K. Vaccine cold chain: part 1. proper handling and storage of vaccine. AAOHN J. 58(8), 337–344; quiz 345 (2010).
   PubMedGoogle Scholar
• Bell KN, Hogue CJ, Manning C, Kendal AP. Risk factors for improper vaccine storage and handling in private provider offices. Pediatrics 107(6), e100 (2001).
   Web of Science ®Google Scholar
• Chen D, Kristensen D. Opportunities and challenges of developing thermostable vaccines. Expert Rev. Vaccines 8(5), 547–557 (2009).
   PubMed Web of Science ®Google Scholar
• Patel J, Kothari R, Tunga R, Ritter NM, Tunga BS. Stability considerations for biopharmaceuticals, Part 1: Overview of protein and peptide degradation pathways. BioProcess Int. 9(1), 20–31 (2011).
   Google Scholar
• Carpenter JF, Pikal MJ, Chang BS, Randolph TW. Rational design of stable lyophilized protein formulations: some practical advice. Pharm. Res. 14(8), 969–975 (1997).
   PubMed Web of Science ®Google Scholar
• Levy Y, Onuchic JN. Water and proteins: a love-hate relationship. Proc. Natl Acad. Sci. USA 101(10), 3325–3326 (2004).
   PubMed Web of Science ®Google Scholar
• Fang WJ, Qi W, Kinzell J, Prestrelski S, Carpenter JF. Effects of excipients on the chemical and physical stability of glucagon during freeze-drying and storage in dried formulations. Pharm. Res. 29(12), 3278–3291 (2012).
   PubMed Web of Science ®Google Scholar
• Yoshioka S, Aso Y. Correlations between molecular mobility and chemical stability during storage of amorphous pharmaceuticals. J. Pharm. Sci. 96(5), 960–981 (2007).
   PubMed Web of Science ®Google Scholar
• Wang W. Lyophilization and development of solid protein pharmaceuticals. Int. J. Pharm. 203(1–2), 1–60 (2000).
   PubMed Web of Science ®Google Scholar
• Chen D, Endres R, Maa YF et al. Epidermal powder immunization of mice and monkeys with an influenza vaccine. Vaccine 21(21-22), 2830–2836 (2003).
   PubMed Web of Science ®Google Scholar
• Chen D, Periwal SB, Larrivee K et al. Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization. J. Virol. 75(17), 7956–7965 (2001).
   PubMed Web of Science ®Google Scholar
• Chen D, Endres RL, Erickson CA, Maa YF, Payne LG. Epidermal powder immunization using non-toxic bacterial enterotoxin adjuvants with influenza vaccine augments protective immunity. Vaccine 20(21–22), 2671–2679 (2002).
   PubMed Web of Science ®Google Scholar
• Chen D, Burger M, Chu Q et al. Epidermal powder immunization: cellular and molecular mechanisms for enhancing vaccine immunogenicity. Virus Res. 103(1–2), 147–153 (2004).
   PubMed Web of Science ®Google Scholar
• Maa YF, Zhao L, Payne LG, Chen D. Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application. J. Pharm. Sci. 92(2), 319–332 (2003).
   PubMed Web of Science ®Google Scholar
• Osorio JE, Zuleger CL, Burger M, Chu Q, Payne LG, Chen D. Immune responses to hepatitis B surface antigen following epidermal powder immunization. Immunol. Cell Biol. 81(1), 52–58 (2003).
   PubMed Web of Science ®Google Scholar
• Maa YF, Shu C, Ameri M et al. Optimization of an alum-adsorbed vaccine powder formulation for epidermal powder immunization. Pharm. Res. 20(7), 969–977 (2003).
   PubMed Web of Science ®Google Scholar
• Maa YF, Ameri M, Rigney R, Payne LG, Chen D. Spray-coating for biopharmaceutical powder formulations: beyond the conventional scale and its application. Pharm. Res. 21(3), 515–523 (2004).
   PubMed Web of Science ®Google Scholar
• Maa YF, Ameri M, Shu C et al. Hepatitis-B surface antigen (HBsAg) powder formulation: process and stability assessment. Curr. Drug Deliv. 4(1), 57–67 (2007).
   PubMedGoogle Scholar
• Chen D, Erickson CA, Endres RL et al. Adjuvantation of epidermal powder immunization. Vaccine 19(20–22), 2908–2917 (2001).
   PubMed Web of Science ®Google Scholar
• Chen D, Zuleger C, Chu Q, Maa YF, Osorio J, Payne LG. Epidermal powder immunization with a recombinant HIV gp120 targets Langerhans cells and induces enhanced immune responses. AIDS Res. Hum. Retroviruses 18(10), 715–722 (2002).
   PubMed Web of Science ®Google Scholar
• Kondo T, McGregor M, Chu Q, Chen D, Horimoto T, Kawaoka Y. A protective effect of epidermal powder immunization in a mouse model of equine herpesvirus-1 infection. Virology 318(1), 414–419 (2004).
   PubMed Web of Science ®Google Scholar
• Gupta RK. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev. 32(3), 155–172 (1998).
   PubMed Web of Science ®Google Scholar
• Morefield GL, Sokolovska A, Jiang D, HogenEsch H, Robinson JP, Hem SL. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 23(13), 1588–1595 (2005).
   PubMed Web of Science ®Google Scholar
• Huleatt JW, Jacobs AR, Tang J et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 25(4), 763–775 (2007).
   PubMed Web of Science ®Google Scholar
• Sokolovska A, Hem SL, HogenEsch H. Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants. Vaccine 25(23), 4575–4585 (2007).
   PubMed Web of Science ®Google Scholar
• Jones LS, Peek LJ, Power J, Markham A, Yazzie B, Middaugh CR. Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J. Biol. Chem. 280(14), 13406–13414 (2005).
   PubMed Web of Science ®Google Scholar
• Marsee DK, Williams JM, Velazquez EF. Aluminum granuloma after administration of the quadrivalent human papillomavirus vaccine. Report of a case. Am. J. Dermatopathol. 30(6), 622–624 (2008).
   PubMed Web of Science ®Google Scholar
• Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 101(11), 4500–4504 (2003).
   PubMed Web of Science ®Google Scholar
• Latz E, Schoenemeyer A, Visintin A et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat. Immunol. 5(2), 190–198 (2004).
   PubMed Web of Science ®Google Scholar
• Kendall M, Mitchell TJ, Costigan G et al. Downregulation of IgE antibody and allergic responses in the lung by epidermal biolistic microparticle delivery. J. Allergy Clin. Immunol. 117(2), 275–282 (2006).
   PubMedGoogle Scholar
• Burger MS, Zuleger CL, Chu Q, Gao X, Payne LG, Chen D. An antigen-independent but not antigen-specific T(H)1 response provides protection in the murine airway inflammation model. J. Allergy Clin. Immunol. 114(6), 1301–1308 (2004).
   PubMed Web of Science ®Google Scholar
• Tosini W, Ciotti C, Goyer F et al. Needlestick injury rates according to different types of safety-engineered devices: results of a French multicenter study. Infect. Control Hosp. Epidemiol. 31(4), 402–407 (2010).
   PubMed Web of Science ®Google Scholar
• Leleux J, Roy K. Micro and nanoparticle-based delivery systems for vaccine immunotherapy: an immunological and materials perspective. Adv. Healthc. Mater. 2(1), 72–94 (2013).
   PubMed Web of Science ®Google Scholar
• Murdan S, Somavarapu S, Ross AC, Alpar HO, Parker MC. Immobilisation of vaccines onto micro-crystals for enhanced thermal stability. Int. J. Pharm. 296(1–2), 117–121 (2005).
   PubMedGoogle Scholar
• Liu Y, Kendall MA. Optimization of a jet-propelled particle injection system for the uniform transdermal delivery of drug/vaccine. Biotechnol. Bioeng. 97(5), 1300–1308 (2007).
   PubMed Web of Science ®Google Scholar
• Kersten G, Hirschberg H. Needle-free vaccine delivery. Expert Opin. Drug. Del 4(5), 459–474 (2007).
   PubMed Web of Science ®Google Scholar